MX2018009861A - Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa. - Google Patents

Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa.

Info

Publication number
MX2018009861A
MX2018009861A MX2018009861A MX2018009861A MX2018009861A MX 2018009861 A MX2018009861 A MX 2018009861A MX 2018009861 A MX2018009861 A MX 2018009861A MX 2018009861 A MX2018009861 A MX 2018009861A MX 2018009861 A MX2018009861 A MX 2018009861A
Authority
MX
Mexico
Prior art keywords
substituted
thiophene
inhibitor
protein kinase
novel compound
Prior art date
Application number
MX2018009861A
Other languages
English (en)
Other versions
MX383812B (es
Inventor
Beom Son Jung
Bo Sim Tae
Young Hur Woo
Man Song Chi
Jong Yoon Ho
Hye Choi Seung
Na Cho Han
Geun Choi Hwan
Doo Kim Nam
Hwa Ko Eun
Kyoung Kim Hyun
Heui Cho Joong
Yong Kang Seock
Young Kim So
Kyung Ko Yi
Yeon Lee Seung
Kyoon Yoon Suk
Hyun Bae Jae
Original Assignee
Korea Inst Sci & Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Inst Sci & Tech filed Critical Korea Inst Sci & Tech
Publication of MX2018009861A publication Critical patent/MX2018009861A/es
Publication of MX383812B publication Critical patent/MX383812B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10—Thiophene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto novedoso de tiofeno 2,3,5-sustituido que tiene actividad inhibidora contra cinasas, un agente anticancerígeno que incluye el compuesto como ingrediente activo, y un método para preparar el compuesto.
MX2018009861A 2016-02-16 2017-02-16 Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa. MX383812B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160017991 2016-02-16
PCT/KR2017/001715 WO2017142325A1 (ko) 2016-02-16 2017-02-16 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물

Publications (2)

Publication Number Publication Date
MX2018009861A true MX2018009861A (es) 2019-06-06
MX383812B MX383812B (es) 2025-03-14

Family

ID=59626142

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009861A MX383812B (es) 2016-02-16 2017-02-16 Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa.

Country Status (15)

Country Link
US (1) US10442796B2 (es)
EP (1) EP3418275B1 (es)
JP (2) JP6749422B2 (es)
KR (3) KR20170096599A (es)
CN (1) CN108884066B (es)
AU (1) AU2017221707B2 (es)
BR (1) BR112018016729B1 (es)
CA (1) CA3014740C (es)
DK (1) DK3418275T3 (es)
ES (1) ES2866890T3 (es)
MX (1) MX383812B (es)
NZ (1) NZ745210A (es)
PT (1) PT3418275T (es)
RU (1) RU2724957C2 (es)
WO (1) WO2017142325A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3014740C (en) * 2016-02-16 2021-06-01 Korea Institute Of Science And Technology 2,3,5-substituted thiophene compound as protein kinase inhibitor
EP3804719A4 (en) * 2018-05-30 2022-03-30 Pharos Ibio Co., Ltd. Use of 2,3,5-substituted thiophene compound for enhancement of radiotherapy
KR102227117B1 (ko) 2018-05-30 2021-03-15 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 유방암 예방, 개선 또는 치료 용도
TWI727392B (zh) 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
KR102578970B1 (ko) * 2020-03-04 2023-09-15 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 난소암 예방, 개선 또는 치료 용도
WO2021177728A1 (ko) * 2020-03-04 2021-09-10 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 난소암 예방, 개선 또는 치료 용도
KR102535842B1 (ko) * 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 비만세포증 예방, 개선 또는 치료 용도
KR102535840B1 (ko) * 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
JP7757528B2 (ja) * 2021-10-14 2025-10-21 ファロス・アイバイオ・カンパニー・リミテッド ２，３，５－置換されたチオフェン化合物を含む併用投与用組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728868A (en) * 1993-07-15 1998-03-17 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
CA2504320A1 (en) * 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
JP2005064770A (ja) * 2003-08-11 2005-03-10 Ricoh Co Ltd 情報処理装置、認証装置、外部装置、証明情報取得方法、認証方法、機能提供方法、証明情報取得プログラム、認証プログラム、機能提供プログラム及び記録媒体
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
DE602004031777D1 (en) 2004-01-05 2011-04-21 Astrazeneca Ab Thiophenderivate als chk-1-inhibitoren
JP2007531757A (ja) * 2004-03-30 2007-11-08 カイロン コーポレイション 抗癌剤としての置換チオフェン誘導体
US20080194552A1 (en) * 2005-03-31 2008-08-14 Astrazeneca Ab Aminopyrimidine Derivatives With Tie2 Inhibiting Activity
KR100703622B1 (ko) * 2005-10-26 2007-04-06 삼성전기주식회사 캡 방식의 카메라 모듈
US9029411B2 (en) * 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
EA024194B8 (ru) * 2011-01-21 2016-11-30 Сан Фарма Адвансед Ресьорч Компани Лтд Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
CA3014740C (en) * 2016-02-16 2021-06-01 Korea Institute Of Science And Technology 2,3,5-substituted thiophene compound as protein kinase inhibitor

Also Published As

Publication number Publication date
JP6749422B2 (ja) 2020-09-02
PT3418275T (pt) 2021-04-22
CA3014740C (en) 2021-06-01
RU2018130703A (ru) 2020-03-17
AU2017221707A1 (en) 2018-08-30
NZ745210A (en) 2019-08-30
KR20180136425A (ko) 2018-12-24
EP3418275B1 (en) 2021-03-17
KR20190035671A (ko) 2019-04-03
CN108884066B (zh) 2021-08-24
RU2724957C2 (ru) 2020-06-29
EP3418275A4 (en) 2019-07-17
CN108884066A (zh) 2018-11-23
CA3014740A1 (en) 2017-08-24
US20190047993A1 (en) 2019-02-14
AU2017221707B2 (en) 2019-10-03
DK3418275T3 (da) 2021-05-10
JP2020143118A (ja) 2020-09-10
BR112018016729A2 (pt) 2018-12-26
HK1258053A1 (zh) 2019-11-01
JP2019504900A (ja) 2019-02-21
WO2017142325A1 (ko) 2017-08-24
ES2866890T3 (es) 2021-10-20
MX383812B (es) 2025-03-14
KR102069730B1 (ko) 2020-01-23
US10442796B2 (en) 2019-10-15
KR20170096599A (ko) 2017-08-24
KR101965326B1 (ko) 2019-04-03
EP3418275A1 (en) 2018-12-26
RU2018130703A3 (es) 2020-03-17
BR112018016729B1 (pt) 2023-10-24

Similar Documents

Publication Publication Date Title
MX2018009861A (es) Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
MX390503B (es) Compuesto de pirimidina fusionada o sal del mismo.
CL2016001895A1 (es) Compuestos
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
DK2970216T3 (da) Biarylamidforbindelser som kinaseinhibitorer
CA2964244C (en) ANTIMICROBIAL COMPOSITION
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
MX2019014041A (es) Inhibidores pirazolicos de magl.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
ECSP19077969A (es) Compuesto heterociclico
JOP20190262B1 (ar) مثبطات بيرازول magl
CO2019011547A2 (es) Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
MX383940B (es) Formulación farmacéutica que contiene tocol fosfato.
BR112017004595A2 (pt) composição farmacêutica contendo inibidor de transportador de fosfato dependente de sódio
BR112018010767A2 (pt) revestimento comestível, sistema de produtos comestíveis apresentando o referido revestimento comestível e uso do referido sistema
MX2017013879A (es) Composiciones que comprenden anakinra.
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
AR109406A1 (es) Compuesto de 1-fenil-3-carbamoilurea y su uso
MX2019002314A (es) Compuesto de 1-acetil-fenil urea, y uso del mismo.
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
MX393608B (es) Profilactico o agente terapeutico para queratitis fungica.
PH12018500176A1 (en) Ameliorating agent for detrusor hyperactivity with impaired contractility
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза